|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.220 USD | -2.13% |
|
-.--% | - |
| 24-12-23 | Guardion Health Sciences, Inc. Declares Cash Dividend, Payable on or Before December 27, 2024 | CI |
| 24-10-15 | Guardion Health Sciences, Inc.(NasdaqCM:GHSI) dropped from S&P TMI Index | CI |
| Market Cap | 4.35M 3.82M 3.57M 3.27M 6.12M 416M 6.28M 42.28M 16.53M 206M 16.32M 15.97M 712M | P/E 2022 |
-0.51x | P/E 2023 | 42.9x |
|---|---|---|---|---|---|
| Enterprise Value | -2.01M -1.77M -1.65M -1.52M -2.84M -193M -2.91M -19.58M -7.66M -95.4M -7.56M -7.39M -330M | EV / Sales 2022 |
-0.16x | EV / Sales 2023 | 0.04x |
| Free-Float |
98.7% | Yield 2022 * |
-
| Yield 2023 | - |
| 1 day | -2.13% |
| 3 years | 3.04 |  | 18 |
| 5 years | 3.04 | | 99 |
| 10 years | 3.04 | | 1,200 |
| Manager | Title | Age | Since |
|---|---|---|---|
Mark Goldstone
CEO | Chief Executive Officer | 62 | 2024-10-17 |
| Corporate Secretary | 74 | - | |
Susan Klein
PRN | Corporate Officer/Principal | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 74 | 2020-06-30 | |
Mark Goldstone
BRD | Director/Board Member | 62 | 2015-05-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 8/26/24 | Sell | 115,540 | 8.9973% | |||
| 3/28/24 | Great Point Capital LLC
| Other | Company | 159,652 | 12.5194% | |
| 6/30/23 | Free | Director | 334 | 0.0264% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.13% | -.--% | -.--% | -56.34% | 4.35M | |
| -0.87% | +4.04% | +58.60% | +163.92% | 1,079B | |
| -0.45% | +3.87% | +57.95% | +52.18% | 640B | |
| +0.04% | +3.95% | +37.69% | +74.54% | 465B | |
| -1.94% | +1.43% | +36.56% | +31.01% | 353B | |
| -1.49% | +0.02% | +34.37% | +40.20% | 301B | |
| -2.33% | +1.02% | +11.48% | +14.59% | 271B | |
| -1.67% | +3.72% | +2.22% | -39.17% | 228B | |
| -1.39% | +5.90% | +27.70% | +64.00% | 209B | |
| -1.18% | +1.83% | +16.20% | +72.69% | 165B | |
| Average | -1.37% | +4.23% | +28.28% | +41.76% | 370.97B | |
| Weighted average by Cap. | -1.29% | +4.86% | +41.28% | +77.73% |
| 2022 | 2023 | |
|---|---|---|
| Net sales | 11.05M 9.71M 9.06M 8.32M 15.57M 1.06B 15.95M 107M 42.03M 524M 41.49M 40.59M 1.81B | 12.25M 10.76M 10.05M 9.22M 17.26M 1.17B 17.68M 119M 46.59M 581M 45.99M 44.99M 2.01B |
| Net income | -14.92M -13.11M -12.24M -11.23M -21.03M -1.43B -21.54M -145M -56.76M -707M -56.03M -54.81M -2.45B | 158K 139K 130K 119K 223K 15.14M 228K 1.54M 601K 7.49M 593K 580K 25.89M |
| Net Debt | -10.65M -9.36M -8.74M -8.02M -15.01M -1.02B -15.38M -104M -40.51M -505M -39.99M -39.12M -1.75B | -6.36M -5.59M -5.22M -4.79M -8.96M -609M -9.18M -61.85M -24.19M -301M -23.88M -23.36M -1.04B |
Employees
9
Sector
Pharmaceuticals
- Stock Market
- Stocks
- GHSI Stock
Select your edition
All financial news and data tailored to specific country editions
